MRI动态增强成像联合血清PRDX6、FOLR1水平检测对乳腺癌的诊断价值-东南大学学报医学版

MRI动态增强成像联合血清PRDX6、FOLR1水平检测对乳腺癌的诊断价值

单位：1. 河南大学第一附属医院医学影像科, 河南开封 475000;
2. 河南大学淮河医院病理科, 河南开封 475000

分类号：R737.9

出版年·卷·期（页码）：2025·44·第四期（599-604）

摘要：

目的:探究磁共振成像(MRI)动态增强成像联合血清过氧化物酶6(PRDX6)、叶酸受体1(FOLR1)检测对乳腺癌的诊断价值。方法:选取2022年11月至2024年11月97例乳腺癌患者为乳腺癌组,另选取97例同期乳腺良性病变患者为对照组。两组均接受MRI动态增强成像检查和酶联免疫吸附法检测血清PRDX6、FOLR1水平。构建受试者工作特征(ROC)曲线分析血清PRDX6、FOLR1水平对乳腺癌诊断能力;四格表法分析MRI动态增强成像联合血清PRDX6、FOLR1水平对乳腺癌诊断价值。结果:与对照组相比,乳腺癌组血清PRDX6、FOLR1表达水平增高;ROC曲线显示血清PRDX6水平诊断乳腺癌曲线下面积(AUC)值为0.808,FOLR1水平的AUC值为0.847,诊断准确度分别为75.77%和79.38%;MRI动态增强成像诊断准确度为84.54%;MRI动态增强成像和血清PRDX6、FOLR1水平与肿瘤直径、TNM分期和淋巴结转移相关(P＜0.05);MRI动态增强成像与血清PRDX6、FOLR1水平检测联合诊断准确度为91.75%,特异度和准确率显著高于单一指标检测(P＜0.05)。结论:乳腺癌患者血清PRDX6、FOLR1水平增高,MRI动态增强成像联合血清PRDX6、FOLR1水平检测对乳腺癌诊断价值较高。

Objective: To explore the diagnostic value of dynamic contrast-enhanced magnetic resonance imaging(MRI) combined with serum peroxiredoxin 6(PRDX6) and folate receptor 1(FOLR1) for breast cancer. Methods: From November 2022 to November 2024, 97 patients with breast cancer were served as breast cancer group, and another 97 patients with benign breast lesions were served as control group. Both groups underwent dynamic contrast-enhanced MRI examination. Enzyme linked immunosorbent assay was used to detect serum PRDX6 and FOLR1. ROC curve was constructed to discuss the diagnostic ability of serum PRDX6 and FOLR1 for breast cancer. In addition, four grid table method was used to discuss the diagnostic value of dynamic contrast-enhanced MRI combined with serum PRDX6 and FOLR1 for breast cancer. Results: Compared with the control group, the breast cancer group had higher serum PRDX6 and FOLR1. ROC curve showed that the AUC value of serum PRDX6 in diagnosis of breast cancer was 0.808, and the AUC value of FOLR1 was 0.847. The diagnostic accuracy was 75.77% and 79.38%, respectively. The diagnostic accuracy of dynamic contrast-enhanced MRI was 84.54%. Dynamic contrast-enhanced MRI, serum PRDX6 and FOLR1 were correlated with tumor diameter, TNM staging, and lymph node metastasis (P<0.05). The combination of dynamic contrast-enhanced MRI, serum PRDX6, and FOLR1 achieved a diagnostic accuracy of 91.75%, with obviously higher specificity and accuracy than single indicator detection(P<0.05). Conclusion: Serum PRDX6 and FOLR1 in breast cancer patients increase. Dynamic contrast-enhanced MRI combined with serum PRDX6 and FOLR1 has high diagnostic value for breast cancer.

参考文献：

[1] SMOLARZ B,NOWAK A Z,ROMANOWICZ H.Breast cancer-epidemiology,classification,pathogenesis and treatment(review of literature)[J].Cancers(Basel),2022,14(10):2569-2596.
[2] OBEAGU E I,OBEAGU G U.Breast cancer:a review of risk factors and diagnosis[J].Medicine(Baltimore),2024,103(3):36905-36911.
[3] WEKKING D,PORCU M,DE SILVA P,et al.Breast MRI:clinical indications,recommendations,and future applications in breast cancer diagnosis[J].Curr Oncol Rep,2023,25(4):257-267.
[4] CHEN Z,INAGUE A,KAUSHAL K,et al.PRDX6 contributes to selenocysteine metabolism and ferroptosis resistance[J].Mol Cell,2024,84(23):4645-4659.
[5] 郑莉,杨侠,黄倩,等.乳腺癌组织中PRDX4、ALG3的表达及与临床病理特征和预后的关系[J].疑难病杂志,2024,23(11):1368-1372.
[6] TUO H,LI X,DU H,et al.FOLR1-stabilized β-catenin promotes laryngeal carcinoma progression through EGFR/AKT/GSK-3β pathway[J].Mol Carcinog,2024,63(1):34-44.
[7] 朱超,张立功,郭晨旭,等.miR-491-5p靶向FOLR1对乳腺癌细胞增殖及侵袭的影响[J].山西医科大学学报,2023,54(10):1338-1346.
[8] 张瑾,陈薇,刘蕾.2017年《NCCN乳腺癌筛查和诊断临床实践指南》(第1版)更新与解读[J].中国全科医学,2017,20(24):2939-2943.
[9] 向泓雨,刘倩,刘荫华.2021版《中华医学会乳腺外科临床实践指南》重点内容解读[J].中国实用外科杂志,2021,41(11):1257-1261.
[10] 中国抗癌协会肿瘤标志专业委员会乳腺癌标志物协作组.基于靶标指导乳腺癌精准治疗标志物临床应用专家共识(2022版)[J].中国癌症防治杂志,2022,14(4):346-362.
[11] YADAV S,BODDICKER N J,NA J,et al.Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM,BRCA1,BRCA2,CHEK2,and PALB2[J].J Clin Oncol,2023,41(9):1703-1713.
[12] 张宇彤,李红梅,张俊,等.乳腺癌术后化疗患者失志综合征变化轨迹及影响因素分析[J].现代医学,2024,52(11):1721-1727.
[13] GEGIOS A R,PETERSON M S,FOWLER A M.Breast cancer screening and diagnosis:recent advances in imaging and current limitations[J].PET Clin,2023,18(4):459-471.
[14] 韩晓凤,侯宗宾,李小潘,等.MRI动态增强成像联合血清PCSK9、TM4SF1诊断乳腺癌的临床价值[J].中国CT和MRI杂志,2024,22(11):89-91.
[15] LAGAL D J,LÓPEZ-GRUESO M J,PEDRAJAS J R,et al.Loss of PRDX6 aborts proliferative and migratory signaling in hepatocarcinoma cell lines[J].Antioxidants(Basel),2023,12(6):1153-1171.
[16] HONG C Q,WENG X F,HUANG X C,et al.A panel of tumor-associated autoantibodies for the detection of early-stage breast cancer[J].J Cancer,2021,12(9):2747-2755.
[17] LI Y,CHEN H,ZHANG H,et al.Identification of oxidative stress-related biomarkers in uterine leiomyoma:a transcriptome-combined mendelian randomization analysis[J].Front Endocrinol(Lausanne),2024,15(1):1373011-1373029.
[18] SEIVA F R F,AGNEIS M L G,DE ALMEIDA M R,et al.In silico analysis of non-conventional oxidative stress-related enzymes and their potential relationship with carcinogenesis[J].Antioxidants(Basel),2024,13(11):1279-1298.
[19] DIBRA D,XIONG S,MOYER S M,et al.Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo[J].Sci Adv,2024,10(7):1835-1850.
[20] VARAGANTI P,BUDDOLLA V,LAKSHMI B A,et al.Recent advances in using folate receptor 1(FOLR1) for cancer diagnosis and treatment,with an emphasis on cancers that affect women[J].Life Sci,2023,326(1):121802-121812.
[21] MATSUNAGA Y,YAMAOKA T,OHBA M,et al.Novel anti-FOLR1 antibody-drug conjugate MORAb-202 in breast cancer and non-small cell lung cancer cells[J].Antibodies(Basel),2021,10(1):6-24.
[22] WANG H C,HUO Y N,LEE W S.Activation of progesterone receptor is essential for folic acid-regulated cancer cell proliferation and migration[J].J Nutr Biochem,2023,112(1):109205-109214.
[23] NAWAZ F Z,KIPREOS E T.Emerging roles for folate receptor FOLR1 in signaling and cancer[J].Trends Endocrinol Metab,2022,33(3):159-174.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录